DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38- resistant variant

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 680-686

  Joto, Noriko ^a   Ishii, Mineko ^a   Minami, Megumi ^a   Kuga, Hiroshi ^a   Mitsui, Ikuo ^a   Tohgo, Akiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 9 ETHYL 5 FLUORO 2,3 DIHYDRO 9 HYDROXY 4 METHYL 1H,12H BENZO PYRANO[3',4':6,7]INDOLIZINO[1,2 B]QUINOLINE 10,13(9H,15H)DIONE MONOMETHANESULFONATE DIHYDRATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; EXATECAN; IRINOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENCY; HUMAN; HUMAN CELL; LUNG CANCER; OAT CELL CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; SOLUBILITY; TOPOTECAN; TUMOR CELLS, CULTURED; WATER;

EID: 0030785681     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<680::AID-IJC21>3.0.CO;2-E     Document Type: Article

References (32)

1. ANDOH, T., ISHII, K., SUZUKI, Y., IKEGAMI, Y., KUSUNOKI, Y, TAKEMOTO, Y. and OKADA, K., Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. nat. Acad. Sci. (Wash.), 84, 5565-5569 (1987).
2. CHANG, J.Y., DETHLEFSEN, L.A., BARLEY, L.R., ZHOU, B.S. and HENG, Y.C., Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43, 2443-2452 (1992).
3. CHEN, A.Y., YU, C., POTMESIL, M., WALL, M.E., WANI, M.C. and LIU, L.F., Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res., 51, 6039-6044 (1991).
4. FUKUOKA, M., NIITANI, H., SUZUKI, A., MOTOMIYA, M., HASEGAWA, K., NISHIWAKI, Y., KURIYAMA, T., ARIYOSHI, Y., NEGORO, S., MASUDA, N., NAKAJIMA, S. and TAGUCHI, T., A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. clin. Oncol., 10, 16-20 (1992).
5. FUTATSUKI, K., WAKUI, A., NAKAO, I., SAKATA, Y, KAMBE, M., SHIMADA, Y., YOSHINO, M., TAGUCHI, T. and OGAWA, N., Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn. J. Cancer Chemorher., 21, 1033-1038 (1994) (in Japanese).
6. GUPTA, R.S., GUPTA, R., ENG, B., LOCK, R.B., Ross, W.E., HERTZBERG, R.P., CARANFA, M.J. and JOHNSON, R.K., Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48, 6404-6410 ( 1988).
7. HENDRICKS, C.B., ROWINSKY, E.K., GROCHOW, L.B. and KAUFMANN, S.H., Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52, 2268-2278 (1992).
8. HERTZBERG, R.P., CARANFA, M.J. and HECHT, S.M., On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28, 4629-4638 (1989).
9. HSIANG, Y.H., HERTZBERG, R., HECHT, S. and LIU, L.F., Camptothecin induces protein-linked DNA break via mammalian DNA topoisomerase I. J. biol. Chem., 260, 14873-14878 (1985).
10. HSIANG, Y.H. and LIU, L.F., Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726 (1988).
11. ISHIDA, Y. and ANDOH, T., Resistance mechanisms related to topoisomerase inhibitors. Jpn. J. Cancer Chemother., 21, 952-961 (1994) (in Japanese).
12. KANZAWA, F., SUGIMITO, M., MINATO, K., KASAHARA, K., BUNGO, M., NAKAGAWA, K., FUJIWARA, Y, LIU, L.F. and SAIJO, N., Establishment of camptothecin analogue (CPT-11 )-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
13. KAPOOR, R., SLADE, D.L., FUJIMORI, A., POMMIER, Y. and HARKER, W.G., Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncology Res., 7, 83-95 (1995).
14. KAWATO, Y., FURUTA, T., AONUMA, M., YASUOKA, M., YOKOKURA, T. and MATSUMOTO, K., Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192-198 (1991).
15. KIJIMA, T., KUBOTA, N. and NISHIO. K., Establishment of a CPT-11-resistant human ovariancancer cell line. Anticancer Res., 14, 799-804 (1994).
16. KUBOTA, N., KANZAWA, F., NISHIO, K., TAKEDA, Y. OHMORI, T., FUJIWARA, Y., TERASHIMA, Y. and SAIJO, N., Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. biophys. Res. Comm., 188, 571-577 (1992).
17. MADELAINE, I., PROST, S., NAUDIN, A., RIOU, G., LAVELLE, F. and RIOU, J.F., Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol., 45, 339-348 (1993).
18. MASUDA, N., FUKUOKA, M., KUSUNOKI, Y., MATSUI, K., TAKIFUJI, N., KUDOH, S., NEGORO, S., NISHIOKA, M., NAKAGAWA, K. and TANAKA, M., CPT-11: a new derivative of camptothecin for treatment of refractory or relapsed small-cell lung cancer. J. clin. Oncol., 10, 1225-1229 (1992).
19. MITSUI, I., KUMAZAWA, E., HIROTA, Y., AONUMA, M., SUGIMORI, M., OHSUKI, S., UOTO, K., EJIMA, A., TERASAWA, H. and SATO, K., A new water-soluble camptothecin derivative, DX-8951f. exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res., 86, 776-782 (1995).
20. MITSUI, I., OHSUKI, S., HIROTA, Y., SUGIMORI, M., TERASAWA, H. and SATO, K., High potency of a camptothecin derivative DX-8951f might be attributed to good membrane permeability. Proc. Amer. Assoc. Cancer Res., 35, 455 (1994).
21. MOSMANN, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
22. NAGAI, S., YAMAUCHI, M., ANDOH, T., NISHIZAWA, M., SATTA, T., KODERA, Y., KONDOU, K., AKIYAMA, S., ITO, K. and TAKAGI, H., Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol. 59, 116-124 (1995).
23. OGASAWARA, H., NISHIO, K., KANZAWA, F., LEE, Y.S., FUNAYAMA, Y., OHIRA, T., KURAISHI, Y., ISOGAI, Y. and SAIJO, N., Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res., 86, 124-129 (1995).
24. OHE, Y. SASAKT, Y., SHINKAI, T., EGUCHI, K., TAMURA, T., KOJIMA, A., KUNIKANE, H., OKAMOTO, H., KARATO, A., OHMATSU, H., KANZAWA, F. and SAIJO, N., Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. nat. Cancer Inst., 84, 972-974 (1992).
25. OHNO, R. and 13 OTHERS. An early phase II study of CPT-11: a new derivative of camptothecin, for treatment of leukemia and lymphoma. J. clin. Oncol., 8, 1907-1912 (1990).
26. SAIJO, N., NISHIO, K., KANZAWA, F., SHINKAI, T., KARATO, A., SASAKI, Y., EGUCHI, K., TAMURA, T., OHE, Y., OSHITA, F. and NISHIO, M., 7-ethyl-10-[4-[(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother. Pharmacol., 34, 112-117 (1994).
27. SHIMADA, Y., YOSHINO, M., WAKUI, A., NAKAO, I., FUTATSUKI, K., SAKATA, Y., KAMBE, M., TAGUCHI, T. and OGAWA, N., Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. clin. Oncol., 11, 909-913 (1993).
28. SUGIMOTO, Y., TSUKAHARA, S., OH-HARA, T., ISOE, T. and TSURUO, T., Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
29. TAKEUCHI, S., TAKAMIZAWA, H., TAKEDA, Y, OKAWA, T., TAMAYA, T., NODA, K., SUGAWA, T., SEKINBA, K., YAKUSHIJI, M. and TAGUCHI, T., Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc. Amer. Soc. clin. Oncol., 10, 189 (1991).
30. TAN, K.B., MATTERN, M.R., ENG, W.K., MCCABE, F.L. and JOHNSON, R.K., Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. nat. Cancer Inst., 81, 1732-1735 (1989).
31. TANIZAWA, A., BEITRAND, R., KOHLHAGEN, G., TABUCHI, A., JENKINS, J. and POMMIER, Y., Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. biol. Chem., 268, 25463-25468 (1993).
32. YANG, C.H.J., HORTON, J.K., COWAN, K.H. and SCHNEIDER, E., Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55, 4004-4009 ( 1995).